ESR1 and breast carcinoma: Recently, some authors described the effect of the addition of HDAC-inhibitors to restore the efficiency of endocrine therapy [3,14,15], for example through re-expression of ESR1 mRNA by trichostatin A or Valproate in ESR1 negative breast cancer cells [16,17].